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APIMProliferating cell nuclear antigen (PCNA), commonly known as a nuclear protein essential for regulation of DNA
replication, DNA repair, and epigenetics, has recently been associated with multiple cytosolic functions. Many
proteins containing one of the two known PCNA-interacting motifs, the AlkB homologue 2 PCNA interacting
motif (APIM) and the PCNA-interacting peptide (PIP)-box, are considered to be mainly cytosolic. APIM is
found in more than 20 kinases and/or associated proteins including several direct or indirect members of the
mitogen-activated protein kinase (MAPK) and PI3K/Akt pathways. Mass spectrometry analysis of PCNA-pull
downs veriﬁed that many cytosolic proteins involved in the MAPK and PI3K/Akt pathways are in complex
with PCNA. Furthermore, treatment of cells with a PCNA-interacting APIM-containing peptide (APIM-peptide)
reduced Akt phosphorylation in human peripheral blood monocytes and a human keratinocyte cell line
(HaCaT). Additionally, the APIM-peptide strongly reduced the cytokine secretion from monocytes stimulated
with toll like receptor (TLR) ligands and potentiated the effects of MAPK and PI3K/Akt inhibitors. Interestingly,
the protein level of the APIM-containing PKR/RIG-1 activator protein (PACT) was initially strongly reduced in
HaCaT cells stimulated with APIM-peptide in combination with the TLR ligand polyinosinic–polycytidylic acid
(polyIC). Our results suggest that PCNA has a platform role in cytosol affecting cellular signaling.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Proliferating cell nuclear antigen (PCNA) is an essential coordinator
of DNA replication and associated processes, including DNA repair and
chromatin/epigenetic maintenance. During these events, PCNA acts
as a DNA sliding clamp/binding platform recruiting and binding other
proteins to ensure genome stability [1,2]. Recently, PCNA has been sug-
gested to act as a binding platform also independent of chromatin and
outside the nucleus. For example, in mature non-proliferating neutro-
phils, PCNA is exclusively located in the cytosol where it serves as a
binding platform for procaspases, inhibits their activation and apoptosis,
and thereby regulates neutrophil survival [3]. We have shown that highngmotif;Co-IP, co-immunopre-
PK, mitogen-activated protein
; PACT, PKR activator protein;
nteracting peptide box; polyIC,
diﬁcation;TLR, toll like receptor.
earch and Molecular Medicine,
e and Technology, NO-7489
6400.
. This is an open access article underlevels of cytosolic PCNA are found in multiple myeloma cells, and that
targeting PCNA with APIM-peptide induces rapid caspase activation
(caspases 3,7, 8 and 9) followed by apoptosis in multiple myeloma,
but not in healthy primary cells [4]. Recently, cytosolic PCNA was
shown to bind and stabilize procaspase-9 in a neuroblastoma cell line,
and interestingly S-nitrosylation of PCNA blocked this interaction
suggesting that the binding is regulated by posttranslational modiﬁca-
tions (PTMs) [5]. Furthermore, PCNA on the cell surface of cancer cells
interacts with the natural cytotoxicity receptor NKp44 on activated
natural killer cells and inhibits their cytotoxic function. This may be a
mechanism for cancer cells to evade antitumor immunity [6,7]. In
addition, proteomic analyses have identiﬁed several putative PCNA-
binding proteins participating in glycolysis [8,9].
Two PCNA-interacting motifs have until now been identiﬁed: the
PCNA-interacting peptide (PIP)-box and the AlkB homologue 2 PCNA-
interacting motif (APIM) [10,11]. We found that overexpression of the
APIM-peptide, or treatment of cells with an APIM-containing cell pene-
trating peptide, reduced growth rate and increased apoptosis when
cancer cells were exposed to chemotherapeutics and/or were stressed,
but not, or far less, under normal conditions. Furthermore, a peptide
with an impaired APIM-sequence, mutAPIM-peptide, had less effect,
thus the APIM–PCNA interaction is required for these activities [4,11].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1479C. Olaisen et al. / Cellular Signalling 27 (2015) 1478–1487We have recently shown that APIM-peptide increases the anti-cancer
activity of melphalan, mitomycin C, and bleomycin in three different
animal models [4,12].
More than 200 different proteins contain APIM and several of these
proteins are involved in cellular signaling, regulating proliferation
and apoptosis, e.g. three direct members of the PI3K/Akt pathway
(p110-α, p110-γ, and PI3K-C2β), proteins regulating PTEN (MAST3
and PLK3), and proteins of the mitogen-activated protein kinase
(MAPK) pathways (ERK8, MK2, MK5, MST4, SOS1, NF1, and TAO1 and
2) [13–20] (see pink proteins in Fig. 1). Thus, cytosolic PCNA may
have a platform/organizer role similar to nuclear PCNA, and APIM–
PCNA interactions might be important in cellular stress responses
others than genotoxic stress.
Toll-like receptors (TLRs) are important for the innate immune
system and recognize pathogen-associated molecular patterns.
TLR-signaling is closely linked to the MAPK, PI3K/Akt, mTOR, and
Wnt signaling pathways, and together these pathways regulate the
expression and secretion of cytokines needed to induce an immune
response. TLR4 on the cell surface of immune cells recognizes among
others lipopolysaccharide (LPS) from Gram-negative bacteria and
TLR3 recognizes dsRNA from viruses and the synthetic dsRNA analog
polyinosinic–polycytidylic acid (polyIC). In addition to TLR3, cytosolic
receptors including RIG-1 and PKR also recognize dsRNA and mediate
antiviral responses via signaling pathways common with the TLR
signaling pathways [14,21]. Upon ligand binding, TLRs recruit the
main adaptor proteins MyD88 and/or TRIF leading to activated TRAF6,
which activates NFκB, several MAPKs, and Akt [13,22–25]. The
MyD88-dependent pathway is used by all TLRs except TLR3. The
adaptor TRIF is recruited by TLR3 and TLR4 and induces in addition
type I interferons (IFNs) via the transcription factor IRF3. It has been
shown that PI3K/Akt activity is required for full activation of IRF3
in the TRIF-dependent pathway during TLR3 and 4 signaling; however,
the exact mechanisms are not clear [26,27]. Arrows in Fig. 1 illustrate
some of the published connections between APIM-containing proteins
(pink), TLR signaling, and the MAPK, PI3K/Akt, andWnt pathways. OurFig. 1. A potential role for cytosolic PCNA in cellular signaling. Schematic overview of known c
dark blue) and the PI3K/Akt, MAPK and NFκB signaling pathways [13–27,32,37–41,57,58,68,6
illustrated in pink [11]. PCNA are illustrated as light blue circles interacting with these prote
inhibition of the APIM-proteins–PCNA interactions.objective was to investigate a possible role of APIM–PCNA interactions
in cellular signaling using TLR-signaling and cytokine response as a
reporter system.
Our data show that isolated PCNA-complexes contain many pro-
teins, including APIM-proteins participating in the MAPK, PI3K/Akt,
and TLR-pathways. Targeting PCNA with APIM-peptide affects cellular
signaling, cell proliferation, and response to TLR stimuli in a spontane-
ously transformed keratinocyte cell line (HaCaT) and in primary cells
(monocytes). Our data suggest a platform/scaffolding role of PCNA
in the cytosol important in cellular signaling.
2. Materials and methods
2.1. Peptides
APIM-peptide (Ac-MDRWLVKWKKKRKIRRRRRRRRRRR [4]),
mutAPIM-peptide (Ac-MDRALVKWKKKRKIRRRRRRRRRRR [4]), R11 (Ac-
RRRRRRRRRRR), and p21 (Ac-MDQTSMRDFYWKKKRKIRRRRRRRRRRR)
were purchased from Innovagen, Sweden.
2.2. Cell line
A spontaneously transformed human keratinocyte cell line, HaCaT,
was cultured in DMEM (Sigma-Aldrich) supplemented with 10% fetal
bovine serum, 2mMglutamine (Sigma-Aldrich), 2.5 μg/ml amphotericin
B (Sigma-Aldrich) and 100 μg/ml gentamicin (Invitrogen). The cells
were cultured at 37 °C in a humidiﬁed atmosphere of 5% CO2.
2.3. Isolation and stimulation of peripheral blood monocytes
Peripheral blood mononuclear cells were isolated from A+ buffy
coats (Blood Bank, St. Olav's University Hospital, Norway) by density
gradient centrifugation (Lymphoprep; Axis-Shield PoC, Norway).
Mononucleated cells were seeded at 4 million cells/ml in serum-free
RPMI 1640 supplemented with glutamine and gentamicin. Afteronnections between the pattern recognition receptors TLRs, PKR and RIG-1 (illustrated in
9,71,78,79]. Proteins containing the APIM-sequence associated with these pathways are
ins. Dashed lines mean pathways possibly deregulated by addition of APIM-peptide and
Table 1
Proteins involved in MAPK, PI3K/Akt, and TLR signaling detected by Orbitrap-mass
spectrometry in PCNA pull downs.
Protein Function Reference
MST4* Activates ERK pathway. [31]
NF1* Negative regulator of Ras. [20]
Pam* Ubiquitin ligase involved in degradation of TSC2/tuberin in
mTOR pathway.
[32]
LRP5 Cell surface co-receptor of Wnt/β-catenin signaling, which
activates mTORC2.
[33,34]
ERK2 Essential component of MAPK/ERK kinase signal
transduction pathway. Regulates cytokine production.
[13]
mTOR Central role in regulating cell growth, metabolism, and
immune function.
[35]
FAK1 Activation of PI3K/Akt, MEK/ERK1/2, and MyD88 pathways.
Regulates NFκB activation and cytokine production.
[36–39]
GSK3β Component of Akt, ERK, mTOR, and Wnt pathways.
Regulatory function in the immune response.
[40–42]
PKN2 Inhibits Akt kinase activity. [43]
STK10 Negative regulator of MEKK1/MAP3K1 and NFκB pathway. [44,45]
PAK1 Activates MEK1. Phosphorylated by Akt. Mast cell
degranulation.
[46–48]
NEMO Activation of the transcription factor NFκB. [49]
CASP-1 Cleaves IL-1β, releasing the mature cytokine. [50]
*Proteins containing the APIM-sequence.
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in medium with 10% heat-inactivated human serum (Blood Bank, St.
Olav's University Hospital). APIM-peptide, mutAPIM-peptide, R11-
peptide, p38 inhibitor (SB203580, 10 μM [Sigma-Aldrich]), PI3K in-
hibitor (LY294002, 5 and 10 μM [Sigma-Aldrich]), and Akt inhibitor
(Akt inhibitor XVIII SC66, 1 μg/ml [Sigma-Aldrich]) were added in
serum-free medium and incubated for 5 min before LPS (10 ng/ml
[Sigma-Aldrich]), polyIC (40 μg/ml [GE Healthcare]), PAM3Cys
(10 ng/ml [Invivogen]) or R848 (10 μg/ml [Invivogen]) were added in
serum-containing medium. The cells were incubated for 4 h before
the supernatants were harvested and frozen prior to further cytokine
analysis by the 27-plex assay (Bio-Plex Pro™ Human cytokine 27-plex
assay). All together monocytes from nine different blood donors
were used in the different experiments. The levels of cytokines and
phosphorylation of Akt varied as expected between the donors; however,
the trends were very reproducible. Number of donors included in each
ﬁgure, and number of reproduced experiments are given in the ﬁgure
legends.
2.4. Flow cytometry
Peripheral blood monocytes were seeded and stimulated as de-
scribed above. For measurement of the apoptotic cell population, the
cells were stained with annexin V-Paciﬁc Blue (Invitrogen) according
to the manufacturer's instructions. Cells were analyzed by a FACSAria
and the FACSDiva software (BD Biosciences).
2.5. Preparation of cell extracts and western analysis
Mononucleated cells were seeded and stimulated as described
above. HaCaT cells were treated with APIM-peptide (12 μM) and polyIC
(2 μg/ml) for 4 h. The cells were harvested, the cell pellet was resus-
pended in 1× packed cell volume of buffer 1 (10 mM Tris–HCl
pH 8.0, 200 mM KCl) and diluted in the same volume (packed cell
volume + buffer 1) of buffer 2 (10 mM Tris–HCl pH 8.0, 200 mM
KCl, 10 mM EGTA, 10 mM MgCl2, 40% glycerol, 0.5% NP40, 1 mM
DTT, 1% phosphatase inhibitor cocktails 1 and 3 [Sigma-Aldrich], 2%
Complete EDTA-free protease inhibitor [Roche], and 2 μl/ml
Omnicleave [Epicentre Technologies]). After incubation for 1.5 h at
4 °C, the cell extracts were centrifuged at 14,000 rpm for 10min. Super-
natants were collected and separated on 10% Bis–Tris gels (NuPAGE,
Invitrogen). After gel electrophoresis, the polyvinylideneﬂuoridemem-
branes (Immobilon, Millipore) were blocked in 50% Odyssey blocking
buffer (LI-COR Bioscience) in TBS. The primary antibodies against (α)
P-Akt (monoclonal, Cell Signalling), PACT (monoclonal, Santa Cruz
Biotechnology Inc.), and β-tubulin (polyclonal, Abcam), as well as the
ﬂuorescently labeled secondary antibodies, goat α-rabbit 680RD
and goat α-mouse 800CW (LI-COR Bioscience) were diluted in 20%
Odyssey blocking buffer in TBST (TBSwith 0.1% Tween20). The proteins
were visualized with the Odyssey infrared imaging system (LI-COR
Bioscience) and quantiﬁed using Odyssey Image Studio V2. Protein
levels were compared to the protein level in untreated cells, which
was set to 100%.β-Tubulinwas used as reference for data normalization.
2.6. Co-immunoprecipitation
HaCaT cells were cross-linked with 0.25% formaldehyde in PBS
for 20min at room temperature. This cross-linkingmethod does not in-
duce massive crosslinking as enzymatically active protein-complexes
capable of base excision repair were recovered using the same method
[28]. The cross-linkingwas stopped by addition of glycine (ﬁnal concen-
tration 0.125 M). After addition of lysis buffers 1 and 2 as described
above, cross-linked extract was sonicated and incubated for 1.5 h at
4 °C before centrifugation at 14,000 rpm for 10 min. Extract was
dialysed at 4 °C overnight in dialysis buffer (10 mM Tris–HCl pH 8.0,
200 mM KCl, 2 mM EDTA, 10% glycerol, 1 mM DTT). α-PCNA (PC10)or mock (α-Τom20) antibodies (Santa Cruz biotechnology Inc.) were
covalently linked to Dynabeads protein A (Life Technologies) with BS3
(Thermo Scientiﬁc) according to the manufacturer's instructions.
Cell extract (2 mg) was subjected to immunoprecipitation with 60 μl
α-PCNA or mock beads under constant rotation at 4 °C overnight. The
beads were washed three times in 10 mM Tris–HCl pH 8.0, 500 mM
KCl and once in 10 mM Tris–HCl pH 8.0 and 50 mM KCl. Tubes were
changed twice between washes. The samples were added 1× LDS
loading buffer containing 1 mM DTT and incubated at 90 °C for 30 min
in order to reverse the cross-links. Proteins were separated by electro-
phoresis for 10min. The gel-laneswere sliced from the gel and subjected
to in-gel tryptic digestion as described [29]. The peptide mixture
after digestion was analyzed on an Orbitrap Elite mass spectrometer
(Orbitrap-MS) equippedwith an Easy nLC 1000UHPLC system (Thermo
Fisher Scientiﬁc). The generated data were analyzed with the Proteome
Discoverer 1.4 software using both Mascot and Sequest HT search
engines against the Swissprot and Uniprot Homo sapiens protein data-
bases (accessed on 2014-08-20). The false discovery rate (FDR) was
set to 1% for proteins and peptides, with a minimum length of 7 amino
acids. Listed proteins in Table 1 and Supplementary Table 1 are detected
solely in the α-PCNA in the second biological replica. Only selected
proteins are listed, and they represent 15% of identiﬁed proteins. In the
ﬁrst biological replica, we detected the same proteins, but some of
these proteins were also detected with low score in the mock-IP, less
than 50% compared to in α-PCNA IP. In the second replica, we changed
the tubes twice before elution as described above.2.7. Immunoﬂuorescence and confocal imaging
HaCaT cells and peripheral blood monocytes were grown on glass
bottom dishes and stained as described using α-PCNA (1:1000)
and Alexa ﬂuor 532 goat α-mouse (Invitrogen) [30]. The nuclei were
stained with DRAQ5 prior to imaging according to the manufacturer's
manual (eBioscience). The ﬂuorescent images were acquired using
a Zeiss LSM 510 Meta laser scanning microscope equipped with a
Plan-Apochromate 63×/1.4 oil immersion objective in 2% FCS in PBS
at RT using the Zeiss LSM 510 software. The stained cells were excited
at λ = 543 nm and detected at λ N= 560–615 for Alexa ﬂuor 532.
DRAQ5 was excited at λ = 633 nm and detected at λ N 650 nm.
The thickness of the slice was 1 μm. All images were acquired with
1481C. Olaisen et al. / Cellular Signalling 27 (2015) 1478–1487consecutive scans. No image processingwas performed, except contrast
and intensity adjustments.
2.8. IFN-β ELISA
Monocytes were stimulated as described above. IFN-βwas measured
in supernatants with the VeriKine-HS™ Human IFN-β Serum ELISA kit
(Pestka Biomedical Laboratories) according to the manufacturer's in-
structions with the following adaptions: the amount of supernatant was
doubled from 50 to 100 μl; sample buffer was reduced from 50 to 25 μl;
and antibody solutionwas reduced from 50 to 25 μl (reducing assay dilu-
ent, keeping the same volume of antibody concentrate and diluent addi-
tive). The OD was measured at 450 nm.
2.9. Cell survival assay
HaCaT cells were seeded into 96-well plates and APIM-peptide
(12 μM) and polyIC (2 μg/ml) were added alone or in combination
at the indicated concentrations. Cells were exposed continuously and
harvested on days one and three using the MTT assay as described
[11]. The average from six wells was used to calculate cell survival.
2.10. In vitro interactions by Microscale Thermophoresis
Measurements (MST)
PCNA was labeled using the RED-Malemide Labeling Kit (Nano-
Temper Technologies). The labeling reaction was performed according
to the manufacturer's instructions in the supplied labeling buffer
applying concentration of 20 μM protein at RT. The ligands (APIM-,
mutAPIM-, R11- and p21-peptides) were dissolved in supplemented
MST buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 10 mM MgCl2)
with 2% fetal bovine serum and incubated for 10 min in RT. A series of
16 1:1 dilutions was prepared in the MST buffer producing ligand
concentrations ranging from 500 μM to 15 nM. Each ligand dilution
was diluted 1:1 with ﬂuorescent labeled PCNA (diluted in MST buffer
to 100 nM) and further incubated for 10 min. Thermophoresis was
measured using Monolith NT.115 instrument (20% MST power and
100% LED power) and Monolith NT Standard Treated Capillaries
(both NanoTemper Technologies, GmbH). Kd was calculated using the
mass action equation by the software NT Analysis 1.5.41 (NanoTemper
Technologies) using ﬂuorescence data from triplicate experiments.
Fluorescence changes caused by binding event were conﬁrmed by
denaturation with 8 M guanidine chloride.
3. Results
3.1. PCNA is in complex with several cytosolic proteins involved in PI3K/Akt
and MAPK signaling
We wanted to investigate PCNA-complexes for cytosolic proteins
because more than 200 of the proteins containing either APIM or
the PIP-box are considered to be mainly cytosolic (http://tare.medisin.
ntnu.no/pcna/index.php). PCNA is found both in the nucleus and
cytosol of HaCaT cells (Fig. 2A), and we therefore performed co-
immunoprecipitation (co-IP) experiments on extracts from these
cells. As suspected, several proteins involved in cellular signaling were
detected speciﬁcally in the PCNA co-IP (selected proteins are shown in
Table 1). This includes the APIM-containing proteins MST4, NF1,
and Pam involved in regulation of ERK and Akt-signaling [20,31]
(APIM-containing proteins are in pink in Fig. 1A and marked with* in
Table 1).
In addition, we detected among others LRP5, ERK2, mTOR, FAK1,
GSK3-β, PKN2, STK10, and PAK1; all proteins involved in regulating
MAPK, NFκB and/or PI3K/Akt pathways [36–39,43–50] (some of these
proteins are included in Fig. 1). Endothelial-cell FAK was recently
shown to be important for DNA-damage induced NFκB activation andthe production of cytokines from endothelial cells [39], and caspase-1
and NEMO, two other proteins found in the PCNA-complexes are
involved in cleaving of the IL-1β precursor and NFκB activation, respec-
tively [49,50]. In addition to the selected proteins listed in Table 1,
we detected classical PCNA-binding proteins such as replication factor
C and ﬂap endonuclease 1 (data not shown). Many of the proteins
pulled down are not APIM- or PIP-box-containing proteins (Table 1
and additional proteins shown in Supplementary Table S1); however,
many of the cytosolic proteins found in the PCNA-complexes are
involved in cellular signaling supporting a role for PCNA in these
processes.
3.2. Targeting PCNA with APIM-peptide in HaCaT cells affects cell growth
and Akt phosphorylation
Many of the proteins detected in the PCNA-complexes are proteins
important in the MAPK and PI3K/Akt pathways, and thereby TLR and
apoptosis signaling. Human keratinocytes respond to polyIC via the
known dsRNA sensing receptors TLR3, PKR, RIG-I, and MDA5 [51–54],
and TLR3 is reported to mediate cell death and release of IL-1β
in keratinocytes in a caspase-4 dependent manner [55]. TLR3 uses
the TRIF/TRAF6 pathways to activate MAPKs, Akt, NFκΒ, and IRF3 [13,
22–27]. RIG-I and PKR trigger activation of p38 and NFκΒ, and NFκΒ
is reported to be regulated via Akt/mTOR [56]. Thus, to explore the
role of PCNA in cellular signaling we examined how APIM-peptides
affected growth of HaCaT cells stimulated with polyIC. We found
that treatment of cells with a cell penetrating APIM-peptide [4], as
well as overexpressed APIM-peptide (APIM-EYFP) [11] increased
the growth inhibitory effects of polyIC (Fig. 2B and C). After 4 h, treat-
ment with APIM-peptide strongly reduced Akt-phosphorylation in
both unstimulated and polyIC-stimulated cells (Fig. 2D, left panel),
and the protein level of the dsRNA-binding APIM-containing PKR/RIG-1
activator protein (PACT) [57,58] was also reduced (Fig. 2E, left panel).
However, after 24 h, APIM-peptide and polyIC, both alone and in combi-
nation, increased the levels of both phosphorylated Akt and PACT after
(Fig. 2D and E, right panels). The effects of the APIM-peptide were
more pronounced in polyIC-stimulated cells, similar to what was previ-
ously seen with cells treated with various chemotherapeutics [4,11,12]
suggesting that the effects of the APIM-peptide are correlated with
the cellular stress responses.
3.3. Targeting PCNA with APIM-peptide in monocytes reduces
Akt-phosphorylation and cytokine secretion after TLR stimulation
Because different cell lines have different sensitivity to the APIM-
peptide [4], we next used Western analysis to examine how the APIM-
peptide affected the PI3K/Akt pathway in primary monocytes isolated
from healthy blood donors. Human primary monocytes contain
substantial amounts of PCNA in the cytosol (Fig. 3A). LPS- and polyIC-
induced Akt-phosphorylation, as well as the basal Akt-phosphorylation
level in monocytes was reduced by treatment with APIM-peptide
(Fig. 3B). Importantly, APIM-peptide alone and in combination with
LPS or polyIC did not induce apoptosis-levels that could explain the
reduction in Akt-phosphorylation (Fig. 3C). We next tested whether
APIM-peptide could affect cytokine secretion frommonocytes stimulated
with different TLR ligands. By measuring the concentration of 27
different cytokines in the cell culture supernatant, we found that
secretion of many LPS-induced cytokines was efﬁciently reduced by
addition of APIM-peptide (Fig. 4A, black bars). Background levels of
cytokines not increased, or increased less than two fold by LPS addition
(deﬁned as “no induction”), were also reduced in some cases (Fig. 4A,
gray bars). Similarly, treatment with APIM-peptide strongly reduced
the polyIC-induced secretion of CXCL10, CCL2, and CCL4 (Fig. 4B).
We found similar reductions in cytokine secretions after stimulation
with the TLR7/8 ligand R848 and the TLR2 ligand PAM3Cys (Supplemen-
tary Fig. S1). In general, fewer cytokines were induced in monocytes
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Fig. 2. APIM-peptide affects Akt phosphorylation and PACT protein levels in polyIC-stimulated HaCaT cells. (A) Confocal ﬂuorescence image of immunoﬂuorescently stained PCNA in
HaCaT cells. Bar, 5 μm. (B) Cell growth (MTT-assay) of polyIC-stimulated (2 μg/ml) HaCaT cells treated with APIM-peptide (12 μM) or (C) expressing APIM-EYFP. Data given are
mean ± SD from six parallel wells from one representative experiment. (D) Quantiﬁcation of Akt Ser473 phosphorylation and (E) PACT protein levels in HaCaT cells treated with
APIM-peptide (12 μM), polyIC (2 μg/ml), and combination of APIM-peptide and polyIC for 4 h (left panels) or 24 h (right panels) byWestern blot analysis. Protein levels were corrected
for loading differences (β-tubulin) and normalized to untreated control cells, which was set to 100. Data are from 3–5 independent experiments. Whisker plots presenting median,
minimum, and maximum values are shown.
1482 C. Olaisen et al. / Cellular Signalling 27 (2015) 1478–1487stimulated with polyIC compared to LPS, R848, and Pam3Cys (black
bars, Figs. 4 and S1). However, our results show that targeting
PCNA with APIM-containing peptides in monocytes affected both
Akt-phosphorylation and cytokine secretion after TLR stimulation.APIM-peptide treatment strongly decreased both thepolyIC-induced
and the basal CXCL10 secretion from monocytes (Fig. 4B, black bar
and Fig. 4A, gray bar, respectively). Induction of CXCL10 expression
is a secondary event and requires the initial secretion of IFN-β. We
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Fig. 3. APIM-peptide reduces Akt phosphorylation in monocytes. (A) Confocal ﬂuorescence image of immunoﬂuorescently stained PCNA (green) in freshly isolated peripheral blood
monocytes. DRAQ5 was used for nuclear staining (red). Bar, 5 μm. (B) Western blot analysis of Akt Ser473 phosphorylation in peripheral blood monocytes stimulated with LPS
(10 ng/ml) or polyIC (40 μg/ml) alone and in combination with APIM-peptide (4 μM) for 4 h. The upper panel shows the quantiﬁcation of phosphorylated Akt corrected for loading
differences (β-tubulin) and normalized to untreated control cells, which were set to 100 (black horizontal line). Data are from one representative donor out of three. (C) Annexin
measurements of peripheral bloodmonocytes treatedwith polyIC (40 μg/ml) or LPS (10 ng/ml) alone and in combinationwith APIM-peptide (4 μM) for 4 h. Results are from two different
blood donors (separated by dashed line).
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stimulated monocytes. Consistent with the reduced CXCL10 secretion,
APIM-peptide treatment decreased the IFN-β secretion (Fig. 4C),
supporting that APIM-peptide affects TLR3/PKR/RIG-1 signaling and
not, or not only, IFN-β/STAT/IRF9 signaling.
We and others have previously shown that the APIM-peptide
interacts with PCNA [4,59]. A mutation in APIM (see Materials and
methods) was found to reduce the ability of APIM-EYFP to co-localize
with PCNA [11], and the corresponding cell penetrating peptide,
mutAPIM-peptide, did not sensitize cells to chemotherapeutics [4].
Microscale thermophoresis measurement (MST) showed that the
mutAPIM-peptide has lower afﬁnity for PCNA than the wild type
APIM-peptide (Fig. 4D). The p21-peptide containing the canonical PIP-
box [2] and the cell-penetrating part of the peptide, R11, were included
as positive and negative controls, respectively. In agreement with this,
we found that the mutAPIM-peptide had little to no effect on the secre-
tion of cytokines after LPS and polyIC stimulation ofmonocytes (Fig. 4E).
Thus, our results support that the cytokine reducing activities observed
are mediated via direct binding of APIM to PCNA.
3.4. APIM-peptide potentiates the effect of MAPK and PI3K inhibitors on
cytokine secretion from monocytes
Because MAPK and PI3K/Akt pathways are important for TLR signal-
ing and cytokine secretion [13,22–26], and many APIM-proteinsparticipate in these pathways, we next tested if the effect of APIM-
peptide on cytokine production from LPS- and polyIC-stimulatedmono-
cytes was enhanced in combinations with inhibitors of p38 MAPK
(SB203580) and class I PI3K (LY294002). The p38 inhibitor reduced
cytokine secretion as a single agent, and in combination with APIM-
peptide a further reduction of many cytokines was detected, both
after LPS and polyIC stimulation (Fig. 5A and B, respectively). The PI3K
inhibitor had less effect on cytokine secretion both alone and in combi-
nationwith APIM-peptide, but still the combination showed an additive
effect on the secretion of some cytokines; largest effects were seen for
IFNγ after LPS, and CCL2–4 after polyIC stimulation (Fig. 5C and D,
respectively). These results further support a role for PCNA in regula-
tion of both these pathways. We also tested direct inhibition of Akt
using the inhibitor SC66 [60], which efﬁciently reduced Akt phos-
phorylation in JJN-3 cells (C. Olaisen and M. Otterlei, unpublished
data). SC66 efﬁciently reduced the secretion of cytokines from LPS-
and polyIC-stimulated monocytes with between 50–99% (Supplemen-
tary Fig. S2), supporting a vital role for Akt in regulation of cytokine
secretion. SC66 may induce apoptosis, but at the dose used in our
study (1 μg/ml) we detected only 13% apoptotic cells in the SC66-
treated versus 8% in the control cells after 24 h. The strong cytokine
inhibitory activity of SC66made it difﬁcult to quantify any combinatory
effectswith the APIM-peptide; however, a further reduction (~30–80%)
in CXCL8 (polyIC only), CCL4 (polyIC only), and TNF (LPS and PolyIC)
was detected. We also examined the effect of APIM-peptide on
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1485C. Olaisen et al. / Cellular Signalling 27 (2015) 1478–1487LPS-induced NFκΒ activation in monocytes. We found a decrease in
NFκB activation after treatment with APIM-peptide in all experiments
performed. The reduction of p65 (RelA) activation after treatment
with LPS (10 ng/ml) in combination with APIM-peptide versus LPS
only was relatively small in the three blood donors tested, 21, 29, and
35% respectively (data not shown).
Taken together, our data support that targeting PCNA with APIM-
peptide has the ability to affect regulation of signaling pathways, includ-
ing the PI3K/Akt and MAPK pathways, two pathways with extensive
crosstalk [61,62]. APIM-peptide blocks interactions of APIM-containing
proteins with PCNA, but likely does not directly inhibit any kinase activ-
ity. Impairing the platform-role of PCNA likely compromises signaling
and pathway crosstalk, resulting in reduced cytokine secretion. These
effects are enhanced when kinase inhibitors are combined with APIM-
peptide.4. Discussion
PCNA has an essential role in coordination of DNA replication and
cellular response to genotoxic stress [2]. Recently, PCNA has also been
linked to regulation of apoptosis [3,4], glycolysis [9], and natural killer-
cell cytotoxicity [63], all processes localized in cytosol. Here we show
that PCNA-complexes pulled down from unstimulated HaCaT cells
contain many proteins involved in cellular signaling. Many of these do
not contain any of the two known PCNA-interacting motifs. However,
their presence in PCNA-complexes is not necessarily due to direct inter-
actions with PCNA. For example, presence of caspase-1 in PCNA com-
plexes could be via indirect interaction of p21 as p21 directly interacts
with several caspases [64] and with PCNA via its PIP-box [2]. We were
not able to deplete the extracts for PCNA, possibly because the epitope
on PCNA recognized by the antibody used was not available in all
1486 C. Olaisen et al. / Cellular Signalling 27 (2015) 1478–1487contexts. Therefore, we have not identiﬁed the complete PCNA interac-
tome using this speciﬁc approach.
PCNA has more than 400 potential interaction partners and the
regulation of different PCNA–protein complexes at a given time is likely
regulated at many levels [2,11,65]. The type of proteins that until now
are veriﬁed to have functional APIM–PCNA interactions, are proteins
important in the cellular response to genotoxic and/or replicative stress,
and it is shown that stress-induced PTMs on PCNA are important
for their interaction with PCNA [4,11,30,59,65,66]. PTMs likely regulate
which binding motif has highest afﬁnity at a given time because the
APIM and PIP-box sequences have overlapping binding regions on
PCNA [4,59]. Our MST analysis indicates that the PIP-box-peptide has
higher afﬁnity for naked recombinant PCNA than the APIM-peptide.
Because stress levels and PTMs on PCNA likely are important for
which proteins are in complex with PCNA at a given time, the protein
repertoire co-IPed with PCNA from different cell types are expected to
be different. Preliminary data from similarly performed co-IP experi-
ments in extracts from JJN3 support this (C. Olaisen and M. Otterlei,
unpublished results). APIM-peptide reduced Akt phosphorylation and
PACT protein levels after 4 h, but an increase was seen after 24 h. This
effect of the APIM-peptide is also likely cell type speciﬁc because
APIM-peptide treatment resulted in a prolonged reduction in Akt-
phosphorylation in the multiple myeloma cell line JJN-3 (N24 h, C.
Olaisen, M. Otterlei; unpublished data), and JJN-3 cells are also much
more sensitive to APIM-peptide than HaCaT cells [4]. Further studies
of the PCNA interactome in several different cell types under different
conditions are required for exploring the role of PCNA in cellular
signaling.
We hypothesize that the APIM-peptide inhibits binding between
PCNA and APIM-containing proteins, such as PACT, and that this affects
various signaling pathways. These effects could be due to reduced
protein stability of APIM-containing proteins when not interacting
with PCNA, e.g. as detected here for PACT and previously shown for
procaspases [3,5]. A platform role of PCNA could also facilitate interac-
tion between several proteins within PCNA-complexes. Nuclear PCNA-
complexes are dynamic and regulated by PTMs during genotoxic stress
[2] and we hypothesize similar regulation of PCNA-interactions in
cytosol in agreement with recent data [5].
In spite of donor variations both in cytokine secretion after TLR
stimulation and in response to the different inhibitors, the overall
results show that the APIM-peptide as well as p38, PI3K, and Akt inhib-
itors reduce the cytokine secretion. The APIM-peptide contains an
Arg-rich cell-penetrating peptide sequence that mediates its cellular
import [4]. It is reported that a different cationic cell-penetrating
peptide reduced the secretion of TNF, IL-6, and IL-8 in LPS-stimulated
THP-1 cells similar to a MK2 inhibitor peptide fused to the same cell-
penetrating peptide, indicating that cell-penetrating peptides them-
selves can alter cellular functions [67]. Our data suggest that APIM-
peptide reduces cytokine secretion via APIM-binding to PCNA because
mutAPIM-peptide with reduced ability to bind PCNA had less effect. In
line with this, the same mutation in the APIM-sequence in the DNA
repair protein XPA and the translesion synthesis protein TFII-I, reduced
the ability of these proteins to interact with PCNA and their functional-
ity in DNA repair and translesion synthesis, respectively, was also
impaired [30,66]. The small observed effects of mutAPIM-peptide
could be a combination of that this peptide had some, but weaker,
ability to interact with PCNA and the potential non-PCNA dependent
effects due to cationic cell penetrating part of the peptide.
In accordance with a vital role of Akt in cytokine production, it
was shown by others that Akt was phosphorylated in response to LPS
and polyIC, and that this plays a vital role in the full activation of
IRF3 [26,68]. A selective inhibitor of PI3K p110-α and γ reduced
LPS-induced Akt-phosphorylation in the human monocytic cell line
THP-1 and IL-6 and TNF secretion from primary peripheral blood
monocytes [69]. Additionally, PI3K p110-γwas recently found to directly
interact with Rab8a and regulate Akt-signaling induced by TLR4 [70].Two members of the class I PI3Ks (p110-α and p110-γ) and in
addition the class II member PI3K-C2β contain the APIM-sequence
and their putative interaction with PCNA could thus potentially be
inhibited by APIM-peptide. Both p110-α (contain APIM) and β are
found to be in a complex with PCNA [71]. Also, a putative reversed
PIP-box sequence found inAkt and a peptide fromPI3Kp85α (regulatory
domain) were found to bind to PCNA in vitro [72].
TheMAPK pathways are also important for expression and secretion
of inﬂammatory cytokines downstream of TLRs. MK2 and MK5, kinases
downstream of p38, contain APIM. MK2 affects cytokine production
by promoting stability and translation of cytokine mRNAs, including
TNF, IL-6, IL-8, IL-10, and IFN-β [73–77]. Interestingly, ERK8, which
also contains APIM, is reported to interact with and stabilize PCNA
[78]. Additional APIM-containing proteins involved in MAPK signaling
are SOS1, MST4, NF1, and TAO 1 and 2 (pink proteins in Fig. 1A). We
found that MST4 and NF1 were co-IPed with PCNA from HaCaT cells
(Table 1). Thus, the data supporting a role for PCNA in cellular signaling
is increasing.5. Conclusions
We found that several proteins involved in cellular signaling were
pulled downwith PCNA from a keratinocyte cell line (HaCaT). Inhibiting
potential PCNA–protein interactions with an APIM-peptide reduced
PI3K/Akt signaling both in HaCaT cells and in primary monocytes.
Our data show that APIM-peptide reduces cytokine secretion
from TLR-stimulated monocytes. We therefore add the possibility that
APIM-mediated PCNA-interactions also play a role in the cellular stress
response to pathogen- and damage-associated molecular patterns,
similar to its importance in the cellular response to genotoxic stress
[11,30,59,65,66]. Our results suggest that targeting PCNA's protein
interactions via APIM may represent a novel approach for treatments
of inﬂammatory disorders.
The APIM-peptide could reduce cytokine secretion from tumor cells
and tumormicroenvironment. Because inﬂammation and cytokines can
be a driver for many cancers, the observed reduction might be a useful
add-on effect of the APIM-peptide in addition to its reported inhibitory
effect of DNA repair [11,30].Conﬂict of interest
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